Dermala – Advancing Microbiome-Powered Skincare Innovation

Ideaship, a venture capital firm by Global Technology Transfer Group, has invested in Dermala to support the growth of personalized skincare solutions powered by microbiome science and digital health technology.

“Upon further discussion with the founder and their primary venture capital investor, we realized an extraordinary opportunity existed within the acne product line,” said Michael Lubitz. “As we worked closely with the company and its stakeholders, we became increasingly impressed by Dr. Rasochova’s resilience and ability to sustain and grow the business around its flagship products. We are now helping optimize the company’s patent portfolio, enterprise value strategy, and next phase of growth.”

Founded by Lada Rasochova, Dermala combines topical skincare, oral supplements, and digital tracking tools to provide science-backed acne treatment alternatives that support microbiome balance and reduce inflammation. The company’s platform moves beyond traditional acne treatments that rely heavily on antibiotics and harsh chemicals.

Dermala is helping redefine acne treatment through personalized, microbiome-powered skincare solutions designed to improve long-term skin health and patient outcomes.

To learn more about Dermala and its microbiome-powered skincare platform, visit their website at www.dermala.com

Contact us about this news
Ideaship
Sammy Lubitz, Strategy Manager
Email: sammy@ideashipfund.com

Dr. Rasochova is a scientist, entrepreneur, and former biotech executive with more than 15 years of experience translating breakthrough science into commercial products. Prior to founding Dermala, she held leadership roles in biotech and pharma, including at Dowpharma, and later led entrepreneurship initiatives at University of California San Diego focused on helping science-driven startups move from lab to market.
Lada Rasochova, Dermala